ALOMIDE Eye drops, solution Ref.[9464] Active ingredients: Lodoxamide

Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Novartis Pharmaceuticals UK Limited, 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ, United Kingdom

Product name and form

ALOMIDE 0.1% w/v.

Pharmaceutical Form
Eye Drops, Solution.

Qualitative and quantitative composition

Alomide contains 0.1% w/v Lodoxamide (as lodoxamide trometamol).

Active Ingredient	Description
Lodoxamide	Lodoxamide is a mast cell stabiliser that inhibits the in vivo Type I immediate hypersensitivity reaction in animals and man.

List of Excipients
Benzalkonium chloride 0.007% w/v Mannitol 4.7 % w/v Hypromellose 0.38% w/v Sodium citrate 0.0415% w/v Citric acid 0.0175% w/v Disodium edetate 0.01% w/v Tyloxapol 0.025% w/v Sodium hydroxide QS pH 5.0 and/or hydrochloric acid QS pH 5.0 Purified water QS 100%

Pack sizes and marketing

ALOMIDE is supplied in 5 mL, 10 mL and 15 mL natural, low-density polyethylene bottles with natural, low density polyethylene dispensing plugs and tamper evident polypropylene screw caps.

Only 5 mL and 10 mL are currently marketed.

Marketing authorization holder

Novartis Pharmaceuticals UK Limited, 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ, United Kingdom

Marketing authorization dates and numbers

PL 00101/0987

5 September 1991 / 3 May 2002

Drugs

Drug	Countries
ALOMIDE	Canada, Finland, Turkey, United States, South Africa

Next: Usage >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.